Molecular mechanism underlying the impact of vitamin D on disease activity of MS

Some previous studies suggest modest to strong effects of 25‐hydroxyvitamin D (25(OH)D) on multiple sclerosis (MS) activity. The objective of this study was to explore the mechanistic rationale that may explain potential clinical effects of 25(OH)D.

[1]  Ludwig Kappos,et al.  Vitamin D as an early predictor of multiple sclerosis activity and progression. , 2014, JAMA neurology.

[2]  F. Barkhof,et al.  Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome , 2014, Multiple sclerosis.

[3]  Adam Santaniello,et al.  Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. , 2013, Human molecular genetics.

[4]  Antonio J. Berlanga-Taylor,et al.  Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease , 2013, BMC Medicine.

[5]  J. Satoh,et al.  Molecular network of chromatin immunoprecipitation followed by deep sequencing-based vitamin D receptor target genes , 2013, Multiple sclerosis.

[6]  E. Hol,et al.  Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. , 2013, Journal of neuropathology and experimental neurology.

[7]  J. Benito-León,et al.  A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis , 2012, Neuroepidemiology.

[8]  Damian Szklarczyk,et al.  STRING v9.1: protein-protein interaction networks, with increased coverage and integration , 2012, Nucleic Acids Res..

[9]  J. Lünemann,et al.  The initiation and prevention of multiple sclerosis , 2012, Nature Reviews Neurology.

[10]  C. McCulloch,et al.  Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis , 2012, Annals of neurology.

[11]  W. Hop,et al.  Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis , 2012, Neurology.

[12]  H. Salamon,et al.  Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis , 2012, The Pharmacogenomics Journal.

[13]  T. Holmøy,et al.  Intrathecal levels of vitamin D and IgG in multiple sclerosis , 2012, Acta neurologica Scandinavica.

[14]  D. Legrand.  Lactoferrin, a key molecule in immune and inflammatory processes. , 2012, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[15]  M. Filippi,et al.  A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  LegrandDominique.  Lactoferrin, a key molecule in immune and inflammatory processes11This article is part of Special Issue entitled Lactoferrin and has undergone the Journal’s usual peer review process. , 2011 .

[17]  V. Beneš,et al.  Nuclear hormone 1α,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy , 2011, Nucleic acids research.

[18]  P. Menheere,et al.  Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis , 2011, Journal of Neuroimmunology.

[19]  L. Kappos,et al.  Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis , 2011, Neurology.

[20]  Gavin Giovannoni,et al.  A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. , 2010, Genome research.

[21]  T. Dwyer,et al.  Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis , 2010, Annals of neurology.

[22]  H. Hartung,et al.  Fingolimod is a potential novel therapy for multiple sclerosis , 2010, Nature Reviews Neurology.

[23]  J. M. Burton,et al.  A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis , 2010, Neurology.

[24]  M. Hewison.  Vitamin D and the immune system: new perspectives on an old theme. , 2010, Endocrinology and metabolism clinics of North America.

[25]  E. Mowry,et al.  Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis , 2010, Annals of neurology.

[26]  I. Simon,et al.  Modulation of the vitamin D3 response by cancer-associated mutant p53. , 2010, Cancer cell.

[27]  M. Brown,et al.  The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. , 2010, Human molecular genetics.

[28]  X. Montalban,et al.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.

[29]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[30]  Mikael Bodén,et al.  MEME Suite: tools for motif discovery and searching , 2009, Nucleic Acids Res..

[31]  A. Norman.  A vitamin D nutritional cornucopia: new insights concerning the serum 25-hydroxyvitamin D status of the US population. , 2008, The American journal of clinical nutrition.

[32]  C. Polman,et al.  Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients , 2008, PloS one.

[33]  Ole Winther,et al.  JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update , 2007, Nucleic Acids Res..

[34]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[35]  A. Norman,et al.  Minireview: vitamin D receptor: new assignments for an already busy receptor. , 2006, Endocrinology.

[36]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[37]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[38]  C L Verweij,et al.  A subtype of multiple sclerosis defined by an activated immune defense program , 2006, Genes and Immunity.

[39]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[40]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Glenville Jones,et al.  Enzymes involved in the activation and inactivation of vitamin D. , 2004, Trends in biochemical sciences.

[42]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[43]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[44]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[45]  F. Barkhof,et al.  Seasonal variation in immune measurements and MRI markers of disease activity in MS , 2002, Neurology.

[46]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[47]  M. Rovaris,et al.  Effects of seasons on magnetic resonance imaging–measured disease activity in patients with multiple sclerosis , 2001, Annals of neurology.

[48]  C. Gössl,et al.  Seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[49]  H. DeLuca,et al.  Two Vitamin D Response Elements Function in the Rat 1,25-Dihydroxyvitamin D 24-Hydroxylase Promoter (*) , 1995, The Journal of Biological Chemistry.

[50]  J E Darnell,et al.  Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. , 1988, Genes & development.

[51]  D. Feldman,et al.  Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells. , 1985, Endocrinology.

[52]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[53]  Hompson,et al.  A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .

[54]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[55]  C. Bonferroni.  Il calcolo delle assicurazioni su gruppi di teste , 1935 .